Our Blog

Welcome to the CERES Regulatory Services blog! Here, you’ll find a wide range of articles and resources on Accelerated Approval Pathways and FDA Fast Track Designation, FDA Breakthrough Therapy Designation, FDA Priority Review Designation, FDA Approval Process, Regulatory Strategy for Therapeutics (Drugs, Biologics, Vaccines, Medical Devices, Cell and Gene Therapy and Advanced Tissue Products), Nonclinical Development, Clinical Development, FDA Meetings, Drug Development Pathways, Expedited Drug Approval, Innovative Therapies Development, NDA and BLA Submission Strategies, FDA Regulatory Guidance, FDA Accelerated and Expedited programs and Strategies of Interest to the Regulatory Scientist.

The Ayvakit Resubmission Journey: From FDA CRL to Approval 

Categories: Clinical Studies
68

Hello Regulatory Scientists, 

Today, let’s explore the journey of Ayvakit (avapritinib) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. 

Regulatory History and Initial Submission 

Drug: Ayvakit (avapritinib) 
Mechanism of Action: Tyrosine kinase inhibitor, specifically targeting mutant forms of the KIT and PDGFRA genes 
Indication: Treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST) with a PDGFRA exon 18 mutation 
Initial Submission Date: June 2019 

The Complete Response Letter (CRL) 

CRL Date: November 2019 
CRL Concerns: 

  1. Safety Data: The FDA requested more comprehensive safety data, particularly regarding the cognitive effects observed in patients. 
  1. Efficacy Data: Concerns were raised about the efficacy data, specifically the need for more robust evidence of clinical benefit. 
  1. Risk Management Plan: Need for a detailed risk management plan to monitor and mitigate potential adverse effects. 

Resubmission Strategy 

Blueprint Medicines, the company behind Ayvakit, implemented a comprehensive strategy to address the FDA’s concerns: 

  1. Additional Clinical Data: Conducted further studies to gather more robust data on the drug’s safety and efficacy, particularly focusing on cognitive effects and clinical benefit. 
  1. Enhanced Safety Monitoring: Provided additional data and analyses on the safety profile, including long-term safety data and management strategies for potential cognitive effects. 
  1. Detailed Risk Management Plan: Developed a robust risk management plan, including monitoring guidelines and patient education materials. 
  1. Continuous FDA Engagement: Maintained open lines of communication with the FDA to ensure alignment on the resubmission strategy and clarify any outstanding questions. 

Resubmission Date: January 2020 

Outcome 

Approval Date: January 2020 
Ayvakit was approved for the treatment of unresectable or metastatic GIST with a PDGFRA exon 18 mutation, providing a new and effective option for patients with this specific genetic profile. 

Lessons Learned 

The journey of Ayvakit from CRL to approval highlights several key lessons for drug developers: 

  1. Comprehensive Data Collection: Providing extensive clinical data, particularly addressing safety concerns, is crucial to addressing FDA concerns. 
  1. Enhanced Safety Monitoring: Ensuring thorough understanding and management of the drug’s safety profile can help mitigate regulatory concerns. 
  1. Effective Risk Management: Developing and implementing a detailed risk management plan can help mitigate potential adverse effects and ensure patient safety. 
  1. Continuous FDA Engagement: Maintaining open and ongoing communication with the FDA helps align development efforts with regulatory expectations. 
  1. Proactive Quality Control: Implementing stringent quality control measures ensures the consistency and reliability of the drug’s production. 

Relevance for Current Drug Developers 

For companies developing drugs today, the Ayvakit case underscores the importance of strategic planning and meticulous attention to detail in the regulatory process. Here are some takeaways to help avoid a CRL and achieve first-cycle approval: 

  1. Thorough Pre-Submission Preparation: Ensure that all aspects of your submission, including safety data and risk management plans, meet FDA standards. 
  1. Proactive Risk Management: Identify and address potential risks early in the development process to prevent issues from arising during FDA review. 
  1. Engage with the FDA Early and Often: Regular interactions with the FDA can provide valuable guidance and help steer the development process. 
  1. Invest in Quality Data: Prioritize the collection of high-quality, detailed safety and efficacy data to support the submission. 
  1. Utilize Advisory Committees: Seek feedback from advisory committees to validate data and address potential concerns, even if formal hearings are not required. 

By learning from the Ayvakit resubmission experience, current drug developers can better navigate the regulatory landscape, avoid common pitfalls, and increase the likelihood of a successful first review cycle approval. 

Stay diligent and strategic, 

CERES Regulatory Services 

Picture of Asad Khan
Asad Khan